bluebird BLUE reported a loss of $4.04 per share in the fourth quarter of 2019, wider than the Zacks Consensus Estimate of a loss of $3.81 and the year-ago quarter’s loss of $2.72.Revenues of $10 million were in line with the Zacks Consensus Estimate. Revenues were down from $19.2 million in the year-ago quarter. The decrease mainly resulted from lower collaboration revenues under the company’s arrangement with Bristol-Myers Squibb BMY.Shares of the company have slumped 33.9% in the past year compared with the industry’s decline of 2.7%. Quarter in DetailR&D expenses escalated to $161.8 million in the fourth quarter of 2019 from $119.7 million a year ago due to costs incurred by the company to advance and expand the pipeline.Selling, general and administrative (SG&A) expenses of $76.2 million were up 42.4% from the year-ago quarter to support the company’s ongoing operations, the overall growth of the pipeline and commercial-readiness activities.2019 ResultsThe company’s loss per share was $14.31, wider than a loss of $10.68 in 2018.The company generated revenues of $44.7 million, down 18.2% year over yearPipeline DevelopmentDuring the quarter, theEuropean Commission granted conditional marketing authorization to LentiGlobin for β-thalassemia, to be marketed as Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy, for patients 12 years or older with TDT, who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.bluebird initiated its rolling Biologics License Application (BLA) submission of LentiGlobin for β-thalassemia for approval in the United States. The company is currently planning to complete the BLA submission in the second half of 2020.In December 2019, the company announced positive top-line data from the pivotal phase II KarMMa study of ide-cel in relapsed and refractory multiple myeloma. The company plans to submit a BLA to the FDA for ide-cel in patients with relapsed and refractory multiple myeloma in the first half of 2020, in partnership with Bristol-Myers Squibb.The company also expects to submit a BLA to the FDA and a marketing authorization application to the European Medicines Agency for Lenti-D in patients with cerebral adrenoleukodystrophy by the end of 2020. bluebird bio, Inc. Price, Consensus and EPS Surprise bluebird bio, Inc. price-consensus-eps-surprise-chart | bluebird bio, Inc. Quote Zacks Rank and Other Stocks to ConsiderCurrently, bluebird is a Zacks Rank #2 (Buy) stock.A few other well-placed stocks in the biotech sector are Aduro Biotech Inc. ADRO and Guardant Health Inc. GH all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Aduro’s loss per share estimates have narrowed from 86 cents to 77 cents for 2020 in the past 60 days.Guardant’s loss per share estimates have narrowed from $1.18 to $1.13 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 39.21%, on average.Free: Zacks’ Single Best Stock Set to Double Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all. This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.See 5 Stocks Set to Double>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report bluebird bio, Inc. (BLUE): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Guardant Health, Inc. (GH): Free Stock Analysis Report To read this article on Zacks.com click here.